Arrowhead Pharmaceuticals (ARWR) Short term Debt (2024 - 2026)

Arrowhead Pharmaceuticals' Short term Debt history runs 3 years deep, the most recent figure standing at $40.0 million for Q1 2026.

• Quarterly Short term Debt fell 38.46% year-over-year to $40.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.0 million (down 38.46% YoY) and the FY2025 annual result came in at $40.0 million, changed N/A from the prior year.
• Short term Debt was $40.0 million for Q1 2026 at Arrowhead Pharmaceuticals, roughly flat from $40.0 million in the prior quarter.
• Across five years, Short term Debt topped out at $65.0 million in Q1 2025 and bottomed at $1.6 million in Q4 2024.
• A 3-year average of $37.8 million and a median of $40.0 million in 2025 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2025 — Short term Debt surged 2361.54% — and 2026, when it sank 38.46%.
• Arrowhead Pharmaceuticals' Short term Debt stood at $1.6 million in 2024, then jumped by 2361.54% to $40.0 million in 2025, then changed by 0.0% to $40.0 million in 2026.
• Business Quant data shows ARWR's Short term Debt at $40.0 million in Q1 2026, $40.0 million in Q4 2025, and $40.0 million in Q3 2025.